8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.

Neuroprotective Effect of Low Frequency-Pulsed Electromagnetic Fields in Ischemic Stroke

Bioeffects Seen

Urnukhsaikhan E, Mishig-Ochir T, Kim S-C, Park J-K, Seo Y-K · 2017

Share:

Low frequency-pulsed electromagnetic field exposure demonstrated neuroprotective effects in a mouse model of ischemic stroke through activation of specific signaling pathways and modulation of cell survival and inflammatory responses.

Plain English Summary

Summary written for general audiences

This study investigated whether low frequency-pulsed electromagnetic fields (LF-PEMFs at 60 Hz, 10 mT) could provide neuroprotective effects in mice following ischemic stroke. The researchers found that LF-PEMF treatment activated the BDNF/TrkB/Akt signaling pathway, increased pro-survival proteins, and decreased pro-apoptotic proteins and inflammatory mediators in stroke-affected mice.

Why This Matters

Ischemic stroke is a leading cause of neurological disability, making investigation of novel therapeutic approaches relevant to clinical practice. The study's focus on molecular signaling pathways and inflammatory mediators provides mechanistic insight into potential neuroprotective mechanisms, though results are from animal models and would require further validation in human studies.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Urnukhsaikhan E, Mishig-Ochir T, Kim S-C, Park J-K, Seo Y-K (2017). Neuroprotective Effect of Low Frequency-Pulsed Electromagnetic Fields in Ischemic Stroke.
Show BibTeX
@article{urnukhsaikhan_e_mishig_ochir_t_kim_s_c_park_j_k_seo_y_k_ce4575,
  author = {Urnukhsaikhan E and Mishig-Ochir T and Kim S-C and Park J-K and Seo Y-K},
  title = {Neuroprotective Effect of Low Frequency-Pulsed Electromagnetic Fields in Ischemic Stroke},
  year = {2017},
  doi = {10.1016/S1474-4422(17)30369-1},
  
}

Quick Questions About This Study

This appears to be a database classification error. The study examines eculizumab pharmaceutical treatment for myasthenia gravis with no electromagnetic field component, making it irrelevant to EMF health research.
No, eculizumab is an intravenous pharmaceutical drug that inhibits complement proteins. The treatment involves no electromagnetic field exposure or EMF-related interventions of any kind.
While both conditions can involve neurological symptoms, myasthenia gravis is an autoimmune disease affecting neuromuscular transmission, distinct from reported electromagnetic hypersensitivity symptoms. Proper medical evaluation distinguishes between them.
The REGAIN trial studied only pharmaceutical intervention with no EMF exposure component. It found no significant difference between drug and placebo for the primary endpoint in myasthenia gravis patients.
No direct relationship exists. Complement inhibitors target immune system proteins, while EMF research examines electromagnetic radiation effects. This study's inclusion in EMF databases appears to be an indexing error.